Top Back to top

Information for Patients & Donors

Improving patients’ lives is the ultimate objective of the EBMT community. While we are not a patient organisation, we are focused on strengthening our connection with patients by making relevant EBMT information more accessible and further explaining the role of important EBMT resources such as The Patient & Donor Registry and our JACIE accreditation body. This page is designed to introduce you to some of the materials that we hope will be of interest. 

COVID-19 and BMT Patients

In the context of the coronavirus disease (COVID-19), the EBMT provides you with an array of useful information and resources.

Learn more

EBMT Registry

The EBMT Registry is the largest patient database of its kind in Europe. Since 1974, it has gathered information on haematopoietic stem cell transplantation procedures, with explicit permission from patients, and provides a pool of data to EBMT members to perform studies, prepare trials, and further knowledge in the field. Its ultimate aim is to improve quality of life and outcome for patients.

See how the Registry is used in Research

Patient Privacy Statement

Read the Statement

Do you want to know more about the Registry? Watch this video

Patient Engagement

Patients, caregivers, donors and health care professionals (HCPs) have complementary strengths and a common goal: optimal outcome after transplantation and cell therapy.

The EBMT Patient Engagement taskforce has been created to promote the active participation of hematopoietic cell transplantation and cell therapy recipients within EBMT.

Patient Advocacy

The EBMT established the Patient Advocacy Committee to ensure that patient perspectives are integrated in EBMT activities.

Patients and patient advocates

Patients and patient advocates involved in HSCT and who are interested in the activities of the EBMT can become Individual Members at a reduced fee

Become a member of the EBMT

JACIE Accreditation information

What does JACIE accreditation mean for patients?

JACIE accreditation offers patients reassurance that a transplant unit is working in line with international standards and has undergone a rigourous inspection process. JACIE establishes minimum requirements for facilities, education and training, quality management, donor and patient management and care, and good cell collection and laboratory practice. 

Endorsed by the experts

JACIE is a joint initiative of the European Group for Blood & Marrow Transplantation (EBMT) and the International Society for Cellular Therapy (ISCT), the two leading scientific organisations in the area of cellular therapy. Both associations are not-for-profit entities. 

International standards

JACIE Accreditation is based on the FACT-JACIE International Standards that are prepared by leading experts from North America, Europe and other regions.

Access the JACIE Standards

National regulations

JACIE accreditation has been incorporated into national regulations in several European countries and is included in a number of national guidelines for bone marrow transplantation. In 2004, JACIE received support from the European Union (EU). An independent review of the EU-funded projects from that period highlighted the success of JACIE and its importance.

Learn more


JACIE has received applications from centres and facilities in more than 20 countries in Europe, Africa and Asia and has performed more than 300 inspections since 2000. JACIE inspectors are all experts in the BMT field. 


Donor Links

The World Marrow Donor Association (WMDA) has a wealth of information useful for donors and patients. Here at the EBMT, our Donor Outcomes Committee is dedicated to collecting robust data on donor outcomes and developing recommendations based on that data. Visit the corresponding pages to learn more. 


Advocacy for patients and implicating ourselves in the legal and regulatory environment in which we work has become an increasingly important focus for the EBMT. The EBMT Legal & Regulatory Affairs Committee has been established to focus on and coordinate actions around these issues, and we are currently participating in four important initiatives:

  1. Innovative Medicines Initiative (IMI) consultation on advanced therapies
  2. HARMONY project that aims to foster better access and care for patients with various haematologic malignancies with the use of big data. 
  3. Partnership agreement between the ONT; EBMT and FACT aimed at ensuring ongoing improvement and the utmost quality in all the clinical procedures necessary for conducting HSCT.
  4. Meeting between the EBMT and DG SANTE - evaluation of the existing tissue and cell legislation that will begin during 2017